Laboratoires Servier

Last updated
Servier
Company type Private
Industry Pharmaceutical
Founded(1954;70 years ago (1954))
Founder Jacques Servier
Headquarters
Suresnes, Île-de-France
,
France
Products Pharmaceuticals
Revenue€4.2 billion (FY 2018)
Number of employees
22,000
Website Official website
Footnotes /references
[1] [2]

Servier Laboratories (French: Laboratoires Servier, often abbreviated to Servier) is an international pharmaceutical company governed by a non-profit foundation, with its headquarters in France (Suresnes). [3]

Contents

The consolidated turnover for the 2018 financial year was €4.2 billion. [4] Servier is the leading French independent pharmaceutical company, and the second largest French pharmaceutical company. It has branches in 149 countries, achieving 82% of its sales outside France. [5] [6] The company reportedly invests a little under 25% of its turnover in research and development, which occupies 3,000 of its 22,000 employees worldwide. [7] The company's production sites produced 853 million drug boxes in 2013. [5]

The Servier Clinical Support Unit in Gidy (near Orléans), which produces drugs for clinical trials, is the largest unit of its kind in Europe. [8] Servier Laboratories is a full member of the European Federation of Pharmaceutical Industries and Associations (EFPIA). [9]

In 2018, Servier finalized the acquisition of Shire’s oncology branch in Boston and named David K. Lee as CEO. The official opening of Servier's new U.S. headquarters took place in 2019. [4]

In 2009, Mediator, an amphetamine-based Servier drug originally developed for weight loss in people with diabetes but often prescribed off-label as a dieting aid, was withdrawn from the market after being linked to 500–2000 deaths in France. [10] [11] Further investigations found that many previous safety alerts on that drug had been either missed or covered up, possibly due to the improper influence of the company. [11]

Product portfolio

Notable products:

Other products:

Collaborative research

As well as internal research and development activities, Servier undertakes publicly funded collaborative research projects with industrial and academic partners. One example, in the area of non-clinical safety assessment, is the InnoMed PredTox. [14] [15] The company is expanding its activities in joint research projects within the framework of the Innovative Medicines Initiative of EFPIA and the European Commission. [16]

In addition to these, Servier engages in research and licensing collaborations across the pharmaceutical and biotechnology industry. These collaborations include:

Servier acquired Symphogen in 2020. [17]

Controversy

Servier Laboratories has been the subject of worldwide scandal for creating and distributing a weight-loss drug called Mediator (Benfluorex), which may have killed up to 2,100 people. [18]

The movie 150 Milligrams , by director Emmanuelle Bercot, features Dr. Irène Frachon discovering that Mediator pills cause heart valve problems/deaths and how in 2009 she starts an uphill battle against the producer and the French health authorities.

In March 2021, Servier was sentenced to a fine of 2.7 million euros for aggravated deception and involuntary manslaughter, however it was acquitted of fraud charges. The court also ordered the company to pay several hundred million euros in damages to the 6,500 plaintiffs, and one of its leading managers was sentenced to four years on probation. The French medical agency ANSM was fined 300,000 euros for failing proper supervision. [19] [20] [21]

Related Research Articles

Schering-Plough Corporation was an American pharmaceutical company. It was originally the U.S. subsidiary of the German company Schering AG, which was founded in 1851 by Ernst Christian Friedrich Schering. As a result of nationalization, it became an independent company. In 1971, the Schering Corporation merged with Plough, Inc. to form Schering-Plough. On November 4, 2009 Merck & Co. merged with Schering-Plough with the new company taking the name of Merck & Co.

<span class="mw-page-title-main">Roche</span> Swiss multinational healthcare company

F. Hoffmann-La Roche AG, commonly known as Roche, is a Swiss multinational healthcare company that operates worldwide under two divisions: Pharmaceuticals and Diagnostics. Its holding company, Roche Holding AG, has shares listed on the SIX Swiss Exchange. The company headquarters are located in Basel. Roche is the fifth-largest pharmaceutical company in the world by revenue and the leading provider of cancer treatments globally. In 2023, the company’s seat in Forbes Global 2000 was 76.

Sanofi S.A. is a French multinational pharmaceutical and healthcare company headquartered in Paris, France. The corporation was established in 1973 and merged with Synthélabo in 1999 to form Sanofi-Synthélabo. In 2004, Sanofi-Synthélabo merged with Aventis and renamed to Sanofi-Aventis, which were each the product of several previous mergers. It changed its name back to Sanofi in May 2011. The company is a component of the Euro Stoxx 50 stock market index.

<span class="mw-page-title-main">Eli Lilly and Company</span> American pharmaceutical company

Eli Lilly and Company is an American pharmaceutical company headquartered in Indianapolis, Indiana, with offices in 18 countries. Its products are sold in approximately 125 countries. The company was founded in 1876 by, and named after, Colonel Eli Lilly, a pharmaceutical chemist and a Union Army veteran of the American Civil War.

<span class="mw-page-title-main">Novo Nordisk</span> Danish pharmaceutical company

Novo Nordisk A/S is a Danish multinational pharmaceutical company headquartered in Bagsværd with production facilities in nine countries and affiliates or offices in five countries. Novo Nordisk is controlled by majority shareholder Novo Holdings A/S which holds approximately 28% of its shares and a majority (77%) of its voting shares.

Toxicogenomics is a subdiscipline of pharmacology that deals with the collection, interpretation, and storage of information about gene and protein activity within a particular cell or tissue of an organism in response to exposure to toxic substances. Toxicogenomics combines toxicology with genomics or other high-throughput molecular profiling technologies such as transcriptomics, proteomics and metabolomics. Toxicogenomics endeavors to elucidate the molecular mechanisms evolved in the expression of toxicity, and to derive molecular expression patterns that predict toxicity or the genetic susceptibility to it.

<span class="mw-page-title-main">Biocon</span> Indian multinational biopharmaceutical company

Biocon Limited is an Indian biopharmaceutical company based in Bangalore. It was founded by Kiran Mazumdar-Shaw in 1978. The company manufactures generic active pharmaceutical ingredients (APIs) that are sold in approximately 120 countries, including the United States and Europe. It also manufactures novel biologics as well as biosimilar insulins and antibodies, which are sold in India as branded formulations. Biocon's biosimilar products are also sold in both bulk and formulation forms in several emerging markets.

Astex Pharmaceuticals ("Astex") is a biotechnology company focused on the discovery and development of drugs in oncology and diseases of the central nervous system. Astex was founded in 1999 by Sir Tom Blundell, Chris Abell & Harren Jhoti, and is located in Cambridge, England.

<span class="mw-page-title-main">Tianeptine</span> Atypical antidepressant

Tianeptine, sold under the brand names Stablon, Tatinol, and Coaxil among others, is an atypical tricyclic antidepressant which is used mainly in the treatment of major depressive disorder, although it may also be used to treat anxiety, asthma, and irritable bowel syndrome.

C.H. Boehringer Sohn AG & Co. KG is the parent company of the Boehringer Ingelheim group, which was founded in 1885 by Albert Boehringer (1861–1939) in Ingelheim am Rhein, Germany. As of 2018, Boehringer Ingelheim is one of the world's largest pharmaceutical companies, and the largest private one. Headquartered in Ingelheim, it operates globally with 146 affiliates and more than 47,700 employees. Unlike most large pharmaceutical companies which are listed, the company is private and fully owned by the Boehringer, Liebrecht and von Baumbach families. The company's key areas of interest are: respiratory diseases, metabolism, immunology, oncology and diseases of the central nervous system. Boehringer Ingelheim is a full member of the European Federation of Pharmaceutical Industries and Associations (EFPIA). The corporate logo of Boehringer Ingelheim depicts a stylized rendition of the central section of the imperial palace of Charlemagne.

<span class="mw-page-title-main">Perindopril</span> High blood pressure medication

Perindopril is a medication used to treat high blood pressure, heart failure, or stable coronary artery disease.

<span class="mw-page-title-main">Gliclazide</span> Chemical compound

Gliclazide, sold under the brand name Diamicron among others, is a sulfonylurea type of anti-diabetic medication, used to treat type 2 diabetes. It is used when dietary changes, exercise, and weight loss are not enough. It is taken by mouth.

<span class="mw-page-title-main">Merck Serono</span> German pharmaceutical company

Merck Serono is a pharmaceutical company headquartered in Darmstadt, Germany, and a brand and division of Merck focused on biopharmaceuticals.

<span class="mw-page-title-main">Johnson & Johnson Pharmaceutical Research and Development</span>

Johnson & Johnson Pharmaceutical Research and Development (J&JPRD) is a subsidiary of Johnson & Johnson that is responsible for discovering and developing pharmaceutical drugs. J&JPRD has research sites located in Raritan, New Jersey, Titusville, New Jersey, Spring House, Pennsylvania, La Jolla, California, Beerse, Belgium and Toledo, Spain.

Benfluorex, sold under the brand name Mediator, is an anorectic and hypolipidemic agent that is structurally related to fenfluramine. It may improve glycemic control and decrease insulin resistance in people with poorly controlled type-2 diabetes.

<span class="mw-page-title-main">Innovative Medicines Initiative</span>

The Innovative Medicines Initiative (IMI) is a European initiative to improve the competitive situation of the European Union in the field of pharmaceutical research. The IMI is a joint initiative of the DG Research of the European Commission, representing the European Communities, and the European Federation of Pharmaceutical Industries and Associations (EFPIA). IMI is laid out as a Joint Technology Initiative within the Seventh Framework Programme. Michel Goldman was the first executive director, from September 2009 until December 2014.

<span class="mw-page-title-main">Glenmark Pharmaceuticals</span> Indian multinational pharmaceutical company

Glenmark Pharmaceuticals Limited is an Indian multinational pharmaceutical company headquartered in Mumbai, India.

Jacques Servier was a French doctor and businessman. He was the founder and president of Laboratoires Servier, a pharmaceutical company.

Corcept Therapeutics Inc. is a pharmaceutical company engaged in the discovery, development and commercialization of drugs for the treatment of severe metabolic, psychiatric and oncologic disorders. Corcept has focused on the adverse effects of excess cortisol, studying new compounds that may mitigate those effects. Its executive team is headed by CEO, president and director Joseph K. Belanoff, MD, and by chief medical officer Robert S. Fishman, MD.

<i>150 Milligrams</i> 2016 film

150 Milligrams is a 2016 French drama film directed by Emmanuelle Bercot. It was screened in the Special Presentations section at the 2016 Toronto International Film Festival. The film is based on the true story of French pulmonologist Irène Frachon, who became noted for her investigations of the serious side effects and deaths attributed to the diabetes drug Mediator, produced by French manufacturer Laboratoires Servier.

References

  1. ↑ "Key figures". Servier. Archived from the original on 2014-10-09. Retrieved 2015-02-03.
  2. ↑ "History". Servier. Archived from the original on 2017-08-05. Retrieved 2015-02-03.
  3. ↑ "French drug maker Servier sets up US headquarters in Seaport". Boston Globe. May 9, 2019.
  4. 1 2 "Servier launches U.S. cancer business with plans to double headcount in next 5 years". Boston Business Journal. May 9, 2019.
  5. 1 2 "SERVIER - Pharmaceutical company specialized in cardiology, diabetes, rheumatology, depression" . Retrieved 2007-07-08.
  6. ↑ "Servier and Galapagos complete enrollment of global ROCCELLA Phase 2 clinical trial with GLPG1972/S201086 in knee osteoarthritis". Bloomberg. June 11, 2019.
  7. ↑ "Servier's US push takes shape as Boston HQ opens". BioPharma Dive. May 9, 2019.
  8. ↑ "Servier UK - Key figures". Archived from the original on 2007-07-08. Retrieved 2007-07-08.
  9. ↑ "The Pharmaceutical Industry in Figures - 2008 Edition". European Federation of Pharmaceutical Industries and Associations (EFPIA). p. 49. Archived from the original on 2008-09-16. Retrieved 2008-08-25.
  10. ↑ Article of the Figaro about Mediator
  11. 1 2 Un doute sur la «sécurité» du Mediator dès 1998 - Libération
  12. ↑ "SERVIER - product portfolio". Archived from the original on 2007-07-02. Retrieved 2007-07-08.
  13. ↑ PR Servier Shire Oncology Acquisition 2018.08.31 Archived 2019-05-17 at the Wayback Machine
  14. ↑ Mattes, William B. (2008). "Public Consortium Efforts in Toxicogenomics". In Mendrick, Donna L.; Mattes, William B. (eds.). Essential Concepts in Toxicogenomics. Methods in Molecular Biology. Vol. 460. pp. 221–238. doi:10.1007/978-1-60327-048-9_11. ISBN   978-1-58829-638-2. PMID   18449490.
  15. ↑ "InnoMed PredTox Member Organizations". Archived from the original on 2008-09-26. Retrieved 2008-08-25.
  16. ↑ Innovative Medicines Initiative. "IMI Call Topics 2008". IMI-GB-018v2-24042008-CallTopics.pdf. European Commission. Archived from the original on 2009-10-15. Retrieved 2008-08-25.
  17. ↑ A/S, Symphogen (3 April 2020). "Servier signed a definitive agreement to acquire Symphogen, a leading antibody discovery company, to boost its antibody capabilities and leverage its R&D pipeline". GlobeNewswire News Room (Press release).
  18. ↑ Samuel, Henry (2019-09-23). "Trial opens in France over weight loss drug that 'killed hundreds'". The Telegraph. ISSN   0307-1235 . Retrieved 2020-04-03.
  19. ↑ Nicolaus Vaux-Montagny, Francois Mori:Paris court convicts, fines pharma firm for deadly diet pill. Houston Chronicle (AP story), 29 March 2021
  20. ↑ French company convicted of manslaughter over deadly diet pill. Al Jazeera English, 29 March 2021
  21. ↑ Mediator drug: French pharmaceutical firm fined over weight loss pill. BBC, 29 March 2021
This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.